A mniotic fluid embolism is characterized by sudden onset of profound hypoxia, hypotension, respiratory and cardiovascular collapse, and consumptive coagulopathy occurring most often during labor, delivery, or the immediate postpartum period. Some 70 yrs after it was first described, amniotic fluid embolism remains one of the leading causes of maternal mortality in the United States and the developed world (1, 2) . The reported incidence of this condition has varied from 1/600 to 1/80,000. This wide range has been attributed to lack of consistency in criteria for diagnosis and absence of an established diagnostic laboratory marker. Historically, the presence of fetal squames or other cells of presumed fetal origin within the maternal pulmonary vasculature was considered pathognomonic for amniotic fluid embolism; however, many women with classic symptoms do not exhibit these findings on histologic examination and squamous cells are found in pulmonary aspirates from women with other illnesses, and even from male patients. Hence, the presence of fetal debris in the pulmonary vasculature is neither required nor sufficient for the diagnosis (2) .
The pathophysiology of amniotic fluid embolism is unclear, but may involve the release of endogenous mediators after the entry of amniotic fluid into the maternal circulation. The thromboplastic effects of tissue factor and phosphatidylserine found in amniotic fluid have been described, and these have been proposed as mediators of the coagulopathy that usually occurs in these patients (3, 4). However, specific mediators responsible for the characteristic pulmonary vasospasm, hypoxia, hypotension, and subsequent cardiovascular collapse have not clearly been identified. The proposed mechanism of mast cell degranulation and histamine release (similar to anaphylaxis) has been investigated by measuring maternal serum tryptase (a marker for mast cell degranulation) and urinary histamine; neither have been useful indicators (5). Decreased complement levels, elevated levels of a specific fetal antigen (sialyl Tn), and the presence of zinc coproporphyrin (a component of meconium) in maternal serum have been investigated and show promise, but the search for a diagnostic laboratory marker continues and amniotic fluid embolism remains a clinical diagnosis of exclusion (5, 6).
In this issue of Critical Care Medicine, Legrand et al (7) investigate insulinlike growth factor binding protein-1 (IGFBP-1) levels in patients with amniotic fluid embolism. The authors selected IGFBP-1 as a potential biomarker because it is considered a specific protein marker of amniotic fluid, originating in decidual cells (8). Elevated concentrations of IGFBP have been found in serum from women with severe preeclampsia and with pregnancies complicated by intrauterine growth restriction (8). The current study included cases referred for review with amniotic fluid embolism based on the criteria outlined by the UK Obstetric Surveillance System, which includes the finding of fetal squames or hair in postmortem lung examination or bronchoalveolar lavage as a sufficient diagnostic criterion. However, it appears that all patients in the study by Legrand et al had clinical symptoms of amniotic fluid embolism ( Fig. 1 in [7] ). The authors found elevated IGFBP in cases of amniotic fluid embolism as compared to levels in critically ill pregnant patients who did not have a clinical diagnosis of amniotic fluid embolism, women with uncomplicated labor or cesarean delivery, and nonpregnant patients with acute pulmonary embolism. Remarkably, elevated IGFBP was both highly sensitive and specific for amniotic fluid embolism in this case control study. It is not clear why one patient in the nonamniotic fluid embolism group who was diagnosed with biopsy-proven acute fatty liver of pregnancy had extremely high levels of IGFBP-1 since this marker has been shown to be inversely correlated to liver fat content (9). Because hepatically derived IGFBP-1 exists in a highly phosphorylated form, and decidual IGFBP-1 exists in a partially or nonphosphorylated isoform, future studies should address phosphoisoforms to clarify this issue (8).
Legrand et al suggest that their findings open up investigation areas of "potential therapeutic implications". I would argue that the significance of this article is not that it will lead directly to new treatment modalities, but rather that its novel results may be used to more clearly differentiate amniotic fluid embolism from other conditions, finally presenting a clear diagnostic biomarker. This would help us better delineate the epidemiology and pathophysiology of amniotic fluid embolism and further our understanding of this often devastating condition, which may in turn lead to targeted disease-specific therapy. L iberation from mechanical ventilation remains one of the most challenging aspects of caring for critically ill patients. Mechanical ventilation is a lifesaving treatment for patients with severe respiratory insufficiency, whereas in other patients the need for ventilatory support is very short and restricted to the perioperative period.
Physicians have always understood that no single approach to weaning from mechanical ventilation is best for all patients. Whereas most patients can be directly extubated after surgery, others may need progressive reduction in ventilatory support before regaining full autonomy. Thus, progressive withdrawal of ventilatory support became the routine for decades. Fortunately, in the 1990s, a group of clinical researchers devoted intense effort to investigating liberation from mechanical ventilation. The group, led by Andres Esteban, demonstrated that up to 80% of patients can safely abandon ventilatory support immediately (1) .
In the last 20 yrs, many groups have investigated the reasons for extubation failure. Indeed, from physiology to epidemiology, it seems that every imaginable factor with any potential to influence patients' ability to recover spontaneous breathing has been studied, and a large body of sometimes contradictory evidence has led to very different conclusions (2-5). Thus, it is often unclear which factors should be considered in the decision-making process.
One study concluded that work of breathing during the spontaneous breathing trial is a good marker of extubation failure because work of breathing was low throughout the weaning trial in successfully extubated patients but increased from normal values to almost twice the original level in those who failed (2) . However, another study found no predictive value for occlusion pressure (P0.1), an easy-to-obtain surrogate for work of breathing (3), although higher P0.1 levels were associated with extubation failure.
On the other hand, weaning failure can develop even in patients with lower ventilatory needs when the ability to manage bronchial secretions is hampered. Therefore, cough strength is a potential predictor of extubation failure; one study found higher Acute Physiology and Chronic Health Evaluation II scores and lower cough peak flow (42 L/min vs. 74 L/ min) in patients who failed to regain spontaneous breathing (4). Nevertheless, the low sensitivity and specificity of this predictor precludes its inclusion in the decision process.
Researchers have tried imaginative approaches to ascertain the factors that might predict the success or failure of weaning trials. To examine patients' ability to recover from the efforts expended during the spontaneous breathing trial, Hernandez et al (5) reconnected the ventilators in patients who had successfully passed a spontaneous breathing trial and found that those who subsequently failed extubation took longer to return to baseline minute ventilation. Perren et al (6) directly asked patients about their self-confidence in assuming spontaneous ventilation and found that the likelihood of failure was higher in non-confident patients.
In this issue of Critical Care Medicine, Soummer et al (7) report their experience with the use of transthoracic ultrasound during weaning. The rationale behind this study is that most patients who fail extubation are unable to maintain aeration of the lungs, either because their lungs have a greater tendency to collapse or because their respiratory muscles lack the endurance necessary to optimally expand their lungs. In any case, the lungs will develop nonaerated or poorly aerated areas during the spontaneous breathing trial. Whereas clinicians have previously tried to elucidate this condition by examining indirect indicators like the oxygenation index, hypercapnia, or intense contraction of accessory respiratory muscles, these investigators used ultrasound to determine the reduction in aerated areas. Thoracic ultrasound has proved reliable in detecting lack of aeration in selected parts of the lungs in different settings (8, 9) . In patients with ventilator-associated pneumonia, the group, led by Rouby (8), demonstrated that bedside lung ultrasound was able to detect the reaeration of selected lung areas in patients who responded to antibiotic treatment and was also able to define areas that remained unaerated in patients who did not respond to the antibiotic treatment. In another study, the same investigators examined the effect of positive end-expiratory pressure in patients with acute respiratory distress syndrome or acute lung injury (9). They found that a higher lung reaeration score was associated with higher positive end-expiratory pressure-induced recruitment, although they also reported that ultrasound was unable to distinguish between normally aerated and hyperinflated areas.
In this context, the study by Soummer et al (7) reports a new
